不同剂量布地奈德混悬液吸入治疗AECOPD165例疗效观察  

A clinical study of Budesonide in the treatment of AECOPD

作　　者：郑岩[1] 谢华[1] 

机构地区：[1]沈阳军区总医院呼吸内科,沈阳110016

出　　处：《陕西医学杂志》2012年第5期535-537,564,共4页Shaanxi Medical Journal

摘　　要：目的:探讨布地奈德混悬液吸入治疗慢性阻塞性肺疾病急性加重期(AECOPD)的临床疗效与安全性。方法:将165例慢性阻塞性肺疾病(COPD)急性加重期患者随机分为大剂量激素吸入组(A组,42例)、一般剂量激素吸入组(B组,40例)、甲强龙组(C组,42例)和对照组(D组,41例)。四组均接受常规治疗,A组在此基础上雾化吸入布地奈德混悬溶液2mg/次,每日2次;B组吸入布地奈德混悬溶液1mg/次,每日2次;疗程均7d。C组予甲强龙40mg/日静点,好转后改为甲泼尼龙片8mg/d口服,共7d。分别于治疗前和治疗第3、7天测定肺功能、血气分析、呼吸困难评分以及记录不良反应。结果:治疗后第3天,A组及C组各参数与D组比较有显著性差异(P<0.05)。治疗后第7天,A、B、C三组与D组比较均有显著性差异(P<0.05)。而A组与B组组间比较无显著性差异(P>0.05)。吸入激素的局部不良反应主要有咽部不适、声音嘶哑等,均明显低于C组(P<0.05)。结论:大剂量吸入布地奈德混悬液治疗AECOPD疗效较为确切。Objective ：To study the clinical effects of nebulized budesonide in the treatment of acute exacerbation of chronic obstructive pulmonary disease（AECOPD）.Methods ：165 patients with AECOPD were randomly divided into 4 groups ： Group A was given conventional treatment and inhaled budesonide,each time 2mg,twice a day.Group B was given conventional treatment and inhaled budesonide,each time 1mg,twice a day.Group C was given conventional treatment and was injected methylpredisolone.Group D was given conventional treatment only.The 4 groups were observed before and after 3 day and the end of treatment.The difference in dyspnea scores,lung function and blood gas analysis were compared.Results ：After treatment,compared with Group D,the differences in dyspnea scores,lung function and blood gas analysis of Group A,B and C were statistically significant（P0.05）.There was not statistically significant（P0.05） among Group A,B and C after end of treatment.After 3 days＇treatment,the differences in corresponding indicators of Group A and C were statistically significant（P0.05）,compared with Group D.The adverse reactions in Group A and B were lower than those in Group C.Conclusion ：The research shows that nebulized budsonide of large dosage is safe and effective.

关 键 词：肺疾病 慢性阻塞性/药物疗法 布地奈德/治疗应用 甲泼尼龙/治疗应用 呼吸疗法 雾化器和汽化器 对比研究 

分 类 号：R563[医药卫生—呼吸系统]